Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (3999)	5/8/1998 5:23:00 PM
From: jack w garnes jr.	Read Replies (1) \| Respond to of 7041

Linda, The company has no earnings...In that they have no approved product. Why are we even talking about earnings???... JG

To: Linda Kaplan who wrote (3999)	5/8/1998 6:43:00 PM
From: Claud B	Read Replies (1) \| Respond to of 7041

<<<But there are no indications that the drug works, not to mention could rival Viagra, since even the best of the info from the tests that we have suggests it doesn't work as well and targets a much smaller population.>>> Here are a couple of direct quotes from Dr. I. Goldstein from his conference call with Oppenheimer this week: "The market opportunity for Vasomax should be large, as 50% of patients do not respond to Viagra,." "Vasomax should be first line therapy for Viagra failures." "Vasomax is wonderfully safe and I will prescribe it when it comes to market." He started the conference by saying he has no investment (stock or options) in any of the companies he has been involved with. (e.g. Pfizer, Vivus, Zonagen, etc.) Now I know there will be those who will say Dr. Goldstein is a shill for Zonagen. Oh well, truth is a wonderful thing. ClaudB